Jounce Therapeutics — Investor Presentation (January 2022)
31 slides from Jounce Therapeutics's investor presentation, Jan 10, 2022
Slide 1: Jounce Therapeutics Corporate Presentation
Jounce Therapeutics Corporate Presentation A NEXT GEN IMMUNOTHERAPY COMPANY JANUARY 2022 Exhibit 99.1
Slide 2: Legal Disclaimer
Legal Disclaimer 2 Various statements concerning our future expectations, plans and prospects, including without limitation, our expectations regarding financial guidance, operating expenses and capital expenditures, the timing, initiation, progress, results of and release of data for clinical trial
Slide 3: The Jounce Difference
Proven Management Team • Founded by IO pioneers: Nobel Coley Lasker Prize • Cash runway through Q3 2023 The Jounce Difference 3 * Out licensed to Gilead Sciences, Inc. The right immunotherapy for the right patient Productive Translational Science Platform • Various immune cell types • Pharmacodynami
Slide 4: The Challenge and Promise of IO Therapy
The Challenge and Promise of IO Therapy Lessons Learned Define New Opportunities 4 *PD-(L)1i = PD-1 inhibitor or PD-L1 inhibitor • Tumor with PD-(L)1i* approval • Minority of pts benefit • Tumor with PD-(L)1i approval • Majority pts do not respond • Tumor with no PD-(L)1i approval • Little to no ben
Slide 5: New Immune Cell Targets Are Needed For Next Gen IO
New Immune Cell Targets Are Needed For Next Gen IO Extend benefit to more patients and realize IO market potential 5 2021 IO Market $37B* 2025 IO market $56B & growing* Next Gen IO T cell-focused • Durable benefit in minority of patients • Many tumor types unresponsive • Majority of combos are chemo
Slide 6: The Core of Our Approach: Translational Science Platform
Human Tumor Samples The Core of Our Approach: Translational Science Platform 6 *PD= Pharmacodynamic Translational Drug Discovery • Sustainable engine • Multiple immune cell types • Goal of new IND every 12 – 18 months Reverse Translational Analysis • Patients with clinical outcomes • PD* and predict
Slide 7: Jounce Immunotherapy Pipeline
DISCOVERY PROGRAMS LILRB1 (ILT2) Myeloid & Lymphoid Bi-Specifics (Not Disclosed) Diverse Immune Cell Types Other Targets (Not Disclosed) PD-(L)1i Resistance Mechanisms Jounce Immunotherapy Pipeline 7 * Formerly JTX-1811 now out-licensed to Gilead Sciences, Inc. Program Target Biology Discovery Precl
Slide 8: Lead Macrophage Program: JTX-8064
Lead Macrophage Program: JTX-8064 8
Slide 9: JTX-8064: Potential Macrophage Checkpoint Inhibitor
JTX-8064: Potential Macrophage Checkpoint Inhibitor LILRB2 / ILT4 Target • LILRB2 is expressed on immunosuppressive macrophages • Immunosuppressive macrophages are a negative prognostic factor for many cancer types • Inhibition of LILRB2 reprograms macrophages to an immune active state and activates
Slide 10: LILRB2 (ILT4) May Inhibit Response to PD-(L)1i Therapy
LILRB2 (ILT4) May Inhibit Response to PD-(L)1i Therapy 10 • CD163 is a general marker for immunosuppressive macrophages • Similar associations between OS and CD163 have been reported for most tumor types in INNATE High LILRB2 / IFNγ Signature Ratio Correlates With Poor Response to PD- (L)1i Treatmen
Slide 11: JTX-8064 Inhibits the Macrophage Checkpoint LILRB2 (ILT4)
JTX-8064 Inhibits the Macrophage Checkpoint LILRB2 (ILT4) 11 Potential to Reverse PD-(L)1i Resistance Cytokine Production Antigen Presentation T-cell Activation JTX-8064 Immunosuppressive Macrophage (M2-like) Immune Activated Macrophage (M1-like)
Slide 12: JTX-8064 Reprograms Macrophages to Enhance T Cell Responses
JTX-8064 Reprograms Macrophages to Enhance T Cell Responses 12 1. Cohen et al., Abstract 5007, AACR 2019; 2. McGrath et al., Abstract 1727, AACR 2021. JTX-8064 reprogrammed macrophages are more effective at stimulating T cells in co-culture2 Reprogramming of macrophages from M2 to an M1 state throug
Slide 13: JTX-8064: INNATE Study Designed to Rapidly Demonstrate POC
JTX-8064: INNATE Study Designed to Rapidly Demonstrate POC Mono and Pimivalimab Combo Dose Escalation and Expansion • Recommended Phase 2 dose 700mg 13 Combo Dose Escalation Completed Oct 2021 7 Tumor Specific Phase 2 Combo Expansion Cohorts Initiated Oct 2021 Clinical Data in 2022 ✓ ✓ HNSCC Ovarian
Slide 14: Translational Informatics Defined Initial Indications
Translational Informatics Defined Initial Indications Higher Lower • Relative evaluation and ranking across all TCGA indications • Focus on 3 key RNA measures (LILRB2, Jounce TAM signature, IFNg signature) • Figure sorted by LILRB2 14 TUMOR TYPE Testicular Cancer Mesothelioma Renal Cancer (clear cel
Slide 15: INNATE is Assessing Eight Cohorts in Seven Different Tumor Types
INNATE is Assessing Eight Cohorts in Seven Different Tumor Types Mechanistic potential to improve effectiveness of T cell-directed therapies 15 Ovarian Cancer (Mono & Combo) No Approved PD-(L)1i (IO Naïve Patients) Head and Neck Squamous Cell Carcinoma Approved PD-1i (IO Naïve Patients) Renal Cell C
Slide 16: Vopratelimab & Pimivalimab
Vopratelimab & Pimivalimab 16
Slide 17: Vopratelimab Value Proposition
Vopratelimab Value Proposition Biological Activity Distinct from CD8 Focused PD-(L)1i • Vopra is an IgG1 agonist antibody selective for ICOS (inducible co-stimulatory of T cells) • Activates CD4 T cells that have been primed by antigen presentation Key Clinical Learnings to Date • Highly durable cli
Slide 18: ICOS hi CD4 T Cells are Associated with Clinical Benefit
ICOS hi CD4 T Cells are Associated with Clinical Benefit 18 *Subset of 44 patients with evaluable blood samples and tumor measurements; based on investigator assessment Pharmacodynamic Biomarker ICONIC Overall Survival by ICOS hi CD4 Status* • Vopra treatment emergent biomarker ICOS hi CD4 T cells a
Slide 19: TISvopra Predicts ICOS hi CD4 Cells and Clinical Benefit
TISvopra Predicts ICOS hi CD4 Cells and Clinical Benefit 19 Predictive Biomarker ICONIC Overall Survival by TISvopra Status • TISvopra predicts for on treatment emergence of ICOS hi CD4 T cells and OS Below TISvopra Cut-Off Median OS = 6.2 mo Above TISvopra Cut-Off Median OS = 16.9 mo Above Biomarke
Slide 20: SELECT: Randomized Phase Predictive Biomarker Study
SELECT: Randomized Phase 2 Predictive Biomarker Study Clinical Study of Two Wholly Owned Antibodies with New Predictive Biomarker Phase 2 SELECT Randomized POC Study • IO naïve 2L NSCLC in ~75 patients selected with TISvopra • Powered to demonstrate statistical superiority of vopra + Pimi versus Pim
Slide 21: Pimivalimab PD-1 inhibitor
Pimivalimab PD-1 inhibitor 21
Slide 22: Pimivalimab (Pimi): PD-1 Inhibitor in POC Combo Studies
Pimivalimab (Pimi): PD-1 Inhibitor in 2 POC Combo Studies Well-Characterized PD-1 Antibody, Fully Human IgG4 Phase 1 Study Results* • 3/18 (16.7%) confirmed responses • No deaths or dose limiting toxicities Opportunities for Pimi • Biomarker selected IO naïve patients (SELECT) • PD-(L)1i naïve & exp
Slide 23: Discovery
Discovery 23
Slide 24: Jounce's Translational Science Platform
Jounce’s Translational Science Platform Deconstructing the Tumor Microenvironment to Identify Novel Therapeutics 24 T cell Identify targets uniquely tied to cell types of interest Profile human tumors for target expression on cell types of interest More IO Responsive Less IO Responsive Targets for l
Slide 25: JTX-1484 (Anti-LILRB4) Development Program
JTX-1484 (Anti-LILRB4) Development Program New addition to our differentiated cell type strategy 25 • Expressed on immuno-suppressive myeloid cells in the TME, including MDSCs, tolerogenic DCs and M2-like macrophages • Potent and specific blocker of human LILRB4 with favorable PK, pre-clinical safet
Slide 26: JTX-1484 (Anti-LILRB4): New Development Program
JTX-1484 (Anti-LILRB4): New Development Program 26
Slide 27: Milestones & Financials
Milestones & Financials 27
Slide 28: Upcoming Milestones
Vopratelimab (SELECT): • SELECT data 2H 2022 JTX-1484 (LILRB4): • Continue to advance towards a 2023 IND Discovery: • Continue to advance multiple new targets through discovery pipeline with a goal of an IND every 12-18 months Upcoming Milestones JTX-8064 (INNATE): • Clinical data in 2022: • Mono an
Slide 29: Financial Strength and Flexibility
Financial Strength and Flexibility NASDAQ: JNCE Strong Balance Sheet • Cash runway through Q3 2023 • Excludes any potential milestone payments • $249M in cash and investments, as of Sept. 30, 2021 Cash Guidance • Year end 2021 cash expected to be ~$220M • 2022 gross cash burn $115M - $130M Common St
Slide 30: The Jounce Difference
The Jounce Difference 30 Opportunity Compelling Pipeline Upcoming Catalysts Financial Strength Clinical data expected in 2022 from both lead programs Next generation IO with discovery across a variety of different immune cell types leading to an extensive pipeline Multiple large market opportunities
Slide 31: Jounce Therapeutics
Jounce Therapeutics JOUNCETX.COM 31
Jounce Therapeutics — Investor Presentation (January 2022) on 6ix